Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05169684 · ClinicalTrials.gov registry record · Phase 2
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT05169684 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 10 participants.
The verdict
NCT05169684, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after novel antiandrogen therapy and have not received chemotherapy for mCRPC.
Interventions
- DRUG Docetaxel
- BIOLOGICAL Nivolumab
- BIOLOGICAL BMS-986218
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2023-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05169684
The ClinicalTrials.gov registry entry for NCT05169684 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT05169684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05169684 about?
NCT05169684 is a clinical study titled "A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after novel antiandroge...
What is the current status of trial NCT05169684?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-02-14. Estimated completion is 2023-12-06.
What interventions are being tested in trial NCT05169684?
The interventions under investigation include: Docetaxel (DRUG), Nivolumab (BIOLOGICAL), BMS-986218 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05169684?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.